Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Developments study discovered that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7